DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and immunotherapy

DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and immunotherapy – Toronto Stock Exchange News Today – EIN Presswire

Trusted News Since 1995

A service for global professionals · Tuesday, January 12, 2021 · 534,413,367 Articles · 3+ Million Readers

News Monitoring and Press Release Distribution Tools

News Topics

Newsletters

Press Releases

Events & Conferences

RSS Feeds

Other Services

Questions?

Copyright © 2019. TSX Stocks
All Rights Reserved